Solid Biosciences Inc.
As of Oct 22, 2026, Solid Biosciences is in Stage 3, the topping phase, now in week 5 (since Sep 23, 2026). It closed at $6.19, 44.5% below its 52-week high and below its 200-day average, which is rising.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is SLDB early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
SLDB among Biotechnology181st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …181 | SLDB | Stage 3 · wk 5 | 57 | −22.8% |
Solid Biosciences: quick answers
What stage is Solid Biosciences in?
As of Oct 22, 2026, Solid Biosciences (SLDB) is in Stage 3, the topping phase. It entered Stage 3 on Sep 23, 2026 and is in week 5. What the four stages mean
Is Solid Biosciences in an uptrend?
Its uptrend has stalled. Solid Biosciences is in Stage 3, the topping phase that follows an advance. It trades 19.0% below its 200-day average, which is rising.
How far is Solid Biosciences from its 52-week high?
Solid Biosciences closed at $6.19 on Oct 22, 2026, 44.5% below its 52-week high of $11.15. Its 52-week low is $3.93.
How has Solid Biosciences performed over the past year?
As of Oct 22, 2026, Solid Biosciences is up 3.0% over the past year and up 13.6% so far in 2026.
Which sector and industry is Solid Biosciences in?
Solid Biosciences is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.